After struggling with its sole drug for years, Marinus rides positive data to a commercialization deal in Europe

After a series of painful setbacks, Marinus had a rebirth of sorts last year when it offered a positive late-stage preview of its sole …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Af­ter strug­gling with its sole drug for years, Mar­i­nus rides pos­i­tive da­ta to a com­mer­cial­iza­tion deal in Eu­rope